Lenalidomide-Induced Ischemic Cerebrovascular Disease in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome

J Stroke Cerebrovasc Dis. 2018 Jun;27(6):e102-e103. doi: 10.1016/j.jstrokecerebrovasdis.2017.12.039. Epub 2018 Feb 1.

Abstract

We describe the case of a 34-year-old woman with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. She developed transient ischemic attack after the introduction of lenalidomide plus dexamethasone (Rd) therapy despite no vascular risk factors. Magnetic resonance and computed tomography angiographies showed bilateral internal carotid artery stenosis. Rd therapy was suspended because of its thromboembolic risk. She had been neurologically stable during the suspension of Rd therapy. After Rd therapy was restarted, however, she repeated ischemic cerebrovascular disease. Rd therapy was switched to carfilzomib plus dexamethasone therapy. Thereafter, she had been neurologically stable. Multivessel stenosis is infrequently seen in POEMS syndrome. Therefore, magnetic resonance angiography should be performed before introducing Rd therapy in POEMS syndrome.

Keywords: POEMS syndrome; cerebral infarction; lenalidomide; multivessel stenosis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Brain / diagnostic imaging
  • Brain / drug effects
  • Brain Infarction / diagnostic imaging
  • Brain Infarction / etiology
  • Dexamethasone / therapeutic use
  • Female
  • Humans
  • Immunologic Factors / adverse effects
  • Immunologic Factors / therapeutic use*
  • Ischemic Attack, Transient / diagnostic imaging
  • Ischemic Attack, Transient / etiology*
  • Lenalidomide
  • Oligopeptides / therapeutic use
  • POEMS Syndrome / complications
  • POEMS Syndrome / diagnostic imaging
  • POEMS Syndrome / drug therapy*
  • Thalidomide / adverse effects
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use

Substances

  • Immunologic Factors
  • Oligopeptides
  • Thalidomide
  • carfilzomib
  • Dexamethasone
  • Lenalidomide